Vivian von Gruenigen, MD

Summa Health Systems

von GrueniganDr. von Gruenigen is a recognized expert in gynecologic oncology and Professor at Northeastern Ohio Medical University. She serves as system Medical Director, Women’s Health Services, Summa Health System and Chair of the Department of Obstetrics and Gynecology at Summa Akron City and St. Thomas Hospitals. She is the Summa Foundation’s Endowed Chair in Women’s Health.

Prior to her position at Summa Health System, Dr. von Gruenigen was director of robotic surgery at University Hospitals Case Medical Center in Cleveland, Ohio. She has received numerous teaching and research awards from multiple institutions. Dr. von Gruenigen has been named one of the “Best Doctors in America” by the Consumer’s Research Council of America as well as one of “America’s Top Oncologists” by Cleveland Magazine. She was honored by the Athena International Leadership organization in 2011 and 2012. In 2012 she was awarded Outstanding Alumni Award for Wright State University, Boonshoft School of Medicine. Also, in 2012 she received the 1st Annual Richard Ireland Award at the World Congress Leadership Summit on Business of Women’s Health.

She is the author of over 100 journal articles and abstracts and is an Editorial Board member at Gynecologic Oncology. Dr. von Gruenigen is a board member of the Foundation for Women’s Cancer, American Board of Obstetrics and Gynecology’s Excellence Foundation and Summa Health System’s Accountable Care Organization. She is a dual board examiner for the American Board of Obstetrics and Gynecology. She also is the principal investigator (PI) for two active NCI funded Gynecologic Oncology Group clinical trials which focus on unmet needs in women with ovarian cancer. Her research has been funded by the government, Lance Armstrong Foundation, the American Cancer Society and the Summa Foundation.

Spotlight

Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.

Awareness

Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.

Research

The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.

Education

The next Ovarian Cancer Survivors Course will be Saturday, July 26, 2014 in Boston. For more information on courses, click here.